News
With Support from Utah Fund of Funds, AlloCure Inc. Closes $14.5 Million Series A Financing Round
July 7, 2008 /
The Utah Fund of Funds and AlloCure Inc, a biotechnology company at the forefront of innovative cell therapies for the treatment of acute kidney injury, announced that Allocure has closed $14.5 million Series A financing. The round was led by SV Life Sciences, a Utah Fund of Funds portfolio firm, with Novo A/S joining the syndicate.
Full Story: http://www.utahbusiness.com/parser.php?nav=email_article&article_id=7262
MATR Supporters (view all)
Posted in: Utah Business and Economic Development
Sorry, we couldn't find any posts. Please try a different search.